



(11) **EP 2 990 477 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72, 73
- (51) Int Cl.:
C12N 7/02 (2006.01) B01D 61/14 (2006.01)
- (48) Corrigendum issued on:
31.10.2018 Bulletin 2018/44
- (45) Date of publication and mention of the grant of the patent:
29.08.2018 Bulletin 2018/35
- (21) Application number: **15186937.7**
- (22) Date of filing: **07.09.2012**

(54) **REMOVAL OF CONTAMINATING VIRUSES FROM AAV PREPARATIONS**
ENTFERNUNG VON KONTAMINATIONSVIREN AUS AAV-PRÄPARATEN
ÉLIMINATION DE VIRUS CONTAMINANTS DE PRÉPARATIONS D'AAV

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR</p> <p>(30) Priority: 08.09.2011 EP 11180594
08.09.2011 US 201161532176 P</p> <p>(43) Date of publication of application:
02.03.2016 Bulletin 2016/09</p> <p>(60) Divisional application:
18191023.3</p> <p>(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
12758663.4 / 2 744 895</p> <p>(73) Proprietor: uniQure IP B.V.
1105 BP Amsterdam (NL)</p> <p>(72) Inventors:
• Hermens, Wilhelmus Theodorus Johannes Maria Christiaan
1105 BP Amsterdam (NL)
• Smith, James Patrick
1105 BP Amsterdam (NL)</p> | <p>(74) Representative: Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague (NL)</p> <p>(56) References cited:
WO-A1-2010/148143 US-B1- 6 479 273</p> <ul style="list-style-type: none">• BURNOUF T ET AL: "NANOFILTRATION OF PLASMA-DERIVED BIOPHARMACEUTICAL PRODUCTS", HAEMOPHILIA, BLACKWELL SCIENCE, OXFORD, GB, vol. 9, no. 1, 1 January 2003 (2003-01-01), pages 24-37, XP001181709, ISSN: 1351-8216, DOI: 10.1046/J.1365-2516.2003.00701.X• BLÜMEL J ET AL: "Wichtige Aspekte der Virussicherheit bei Neuartigen Therapien", BUNDESGESUNDHEITSBLATT - GESUNDHEITSFORSCHUNG - GESUNDHEITSSCHUTZ, SPRINGER, BERLIN, DE, vol. 53, no. 1, 26 November 2009 (2009-11-26), pages 38-44, XP019765204, ISSN: 1437-1588 |
|---|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 990 477 B8

- **BLÜMEL J:** "Virus Safety Aspects of Advanced Therapies", DGRA-Symposium "Advanced Therapy Medicinal Product Development and Regenerative Medicine", Paul-Ehrlich-Institut, Langen, Germany, 25-26th November 2008, 26 November 2008 (2008-11-26), pages 1-18, XP055016970, Retrieved from the Internet: URL:http://www.dgra.de/fortbildung/pdf/workshops/20081125_pei/4-5-bluemel.pdf [retrieved on 2012-01-19]
- **RUEDA P ET AL:** "Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 7-8, 22 November 2000 (2000-11-22), pages 726-734, XP27355281, ISSN: 0264-410X [retrieved on 2000-11-22]
- **KERN G:** "Virus removal by filtration", BIOPHARM INTERNATIONAL, vol. 19, no. 10, 1 January 2006 (2006-01-01), pages 32-41, XP055017438,